How Many Doses in an MK-677 Vial? (Real-World Breakdown)

A single 10mg MK-677 vial can yield anywhere from 10 to 40 individual doses—but that range isn't arbitrary. The number of doses you extract depends entirely on two variables: the volume of bacteriostatic water you add during reconstitution and the target dose per administration in your research protocol. Most researchers fixate on the peptide quantity (10mg, 15mg, 20mg) printed on the vial label without recognizing that reconstitution volume is what determines dose count in practice. Miss this relationship and you'll either run out of material mid-protocol or dilute your solution so heavily that accurate measurement becomes impossible.

Our team has worked with hundreds of research labs navigating peptide dosing protocols. The confusion around doses per vial stems from one core misunderstanding: lyophilised peptides don't arrive in ready-to-use form—you create the final concentration yourself when you add solvent.

How many doses are in a standard MK-677 vial?

A 10mg MK-677 vial reconstituted with 2mL bacteriostatic water at a target dose of 25mg/kg (approximately 0.5mg per administration for research models) yields 20 doses. Reconstitute the same vial with 1mL water instead and the dose count drops to 10 at the same target concentration. The vial's peptide content is fixed—dose count scales with dilution.

Here's what creates the variability: MK-677 (ibutamoren) is supplied as lyophilised powder in vials ranging from 5mg to 25mg total peptide content. The most common research-grade format is 10mg per vial. When you reconstitute that 10mg with bacteriostatic water, you determine the final concentration—measured in mg/mL—which then dictates how many microliters you withdraw per dose. A research protocol calling for 0.25mg per administration from a 10mg vial reconstituted with 2mL water requires 50μL per dose (0.25mg ÷ 5mg/mL = 0.05mL), yielding 40 total doses. Double the target dose to 0.5mg and the vial now provides 20 doses. This piece covers exactly how reconstitution math works, what preparation mistakes collapse dose accuracy, and why vial formats and concentration targets matter more than peptide quantity alone.

Understanding MK-677 Vial Formats and Peptide Content

MK-677 vials are sold by total peptide mass—not volume. A '10mg vial' contains 10 milligrams of lyophilised ibutamoren powder, typically occupying less than 0.1mL of visible material at the vial bottom. This is not a liquid product. The powder must be reconstituted with bacteriostatic water before use, and the volume you add determines final concentration. Standard research-grade formats include 5mg, 10mg, 15mg, 20mg, and 25mg vials—each representing total peptide content per container.

The number of doses vial MK-677 contains depends on your reconstitution protocol. If you add 1mL bacteriostatic water to a 10mg vial, the resulting solution contains 10mg/mL. A 0.5mg research dose requires 0.05mL (50μL) per administration—yielding 20 total doses from that vial. Add 2mL water instead and the concentration drops to 5mg/mL. The same 0.5mg dose now requires 0.1mL (100μL) per administration—still yielding 20 doses, but with double the injection volume. This is the core relationship: peptide mass ÷ solvent volume = concentration; concentration × withdrawal volume = dose per administration.

Purity matters for dose accuracy. Research-grade MK-677 from Real Peptides undergoes third-party HPLC verification to confirm ≥98% purity. A 10mg vial at 98% purity contains 9.8mg active ibutamoren—the remaining 0.2mg is residual manufacturing byproducts or excipients. Lower-purity sources (90–95%) contain proportionally less active compound, which skews dose calculations if you assume 100% purity. Always factor verified purity into your reconstitution math. Our MK 677 product ships with batch-specific purity certificates—eliminating guesswork from concentration calculations.

Reconstitution Volume: The Variable That Determines Dose Count

Reconstitution volume is the single largest determinant of how many doses vial MK-677 yields. The peptide content is fixed—10mg in a 10mg vial—but the volume of bacteriostatic water you add creates the final working concentration. Standard reconstitution volumes for research peptides range from 1mL to 3mL depending on target dose size and injection volume preferences. Smaller reconstitution volumes (1mL) produce highly concentrated solutions requiring smaller withdrawal volumes per dose—ideal for protocols using insulin syringes with 0.3mL maximum capacity. Larger volumes (2–3mL) create more dilute solutions requiring larger withdrawals—easier to measure accurately with standard 1mL syringes but consuming more solvent per vial.

The math is direct. A 10mg vial reconstituted with 1mL bacteriostatic water yields 10mg/mL concentration. A research protocol targeting 0.25mg per dose requires 0.025mL (25μL) per administration. Total doses: 10mg ÷ 0.25mg = 40 doses. Reconstitute the same vial with 2mL and concentration drops to 5mg/mL. The same 0.25mg dose now requires 50μL per administration—but total dose count remains 40 because you're still dividing 10mg total peptide by 0.25mg per dose. The variable that changes is injection volume per dose, not dose count—assuming your syringe can accurately measure the required volume.

Here's where practical limits matter. Insulin syringes (0.3mL or 0.5mL capacity) measure down to 1μL increments reliably but cannot withdraw volumes exceeding their barrel capacity. If your reconstitution creates a concentration requiring 0.4mL per dose, a 0.3mL syringe physically cannot deliver that dose—you'd need to switch to a 1mL syringe or increase reconstitution volume to lower per-dose requirements. Conversely, extremely concentrated solutions (20mg/mL) requiring only 12.5μL per dose push measurement accuracy to syringe detection limits. Reconstitution volume should be chosen to place your per-dose withdrawal in the 25–200μL range for insulin syringes or 0.1–0.8mL for 1mL syringes—the zones where graduated markings allow reliable measurement.

Dose Calculation Formula and Real-World Examples

Dose count from any MK-677 vial follows one formula: total peptide content (mg) ÷ target dose per administration (mg) = total doses. This is true regardless of reconstitution volume—changing solvent quantity alters concentration and withdrawal volume but not total available doses. A 10mg vial targeting 0.5mg per dose yields 20 doses whether reconstituted with 1mL, 2mL, or 3mL water. What changes is how much liquid you withdraw each time.

Example 1: A 15mg MK-677 vial reconstituted with 1.5mL bacteriostatic water creates 10mg/mL concentration. Target dose: 0.3mg per administration. Calculation: 0.3mg ÷ 10mg/mL = 0.03mL (30μL) per dose. Total doses: 15mg ÷ 0.3mg = 50 doses. Each administration requires 30μL withdrawal—well within insulin syringe accuracy range.

Example 2: A 10mg vial reconstituted with 2mL water yields 5mg/mL. Target dose: 1mg per administration. Calculation: 1mg ÷ 5mg/mL = 0.2mL (200μL) per dose. Total doses: 10mg ÷ 1mg = 10 doses. Each dose requires 200μL—approaching the upper limit for 0.3mL insulin syringes but easily measured with 1mL syringes.

Example 3: A 20mg vial reconstituted with 2mL water creates 10mg/mL concentration. Target dose: 0.25mg. Calculation: 0.25mg ÷ 10mg/mL = 0.025mL (25μL) per dose. Total doses: 20mg ÷ 0.25mg = 80 doses. This format is common in extended research protocols requiring frequent low-dose administrations over months.

Purity corrections: if your vial's HPLC certificate indicates 96% purity instead of 100%, multiply the stated peptide content by 0.96 before dose calculations. A '10mg' vial at 96% purity contains 9.6mg active compound. Target dose 0.5mg: 9.6mg ÷ 0.5mg = 19.2 doses (round down to 19 for safety margin). Ignoring purity inflates dose count by 4% in this example—small but meaningful in multi-vial protocols.

MK-677 Vial Formats: Full Comparison

| Vial Format | Reconstitution Volume | Final Concentration | Target Dose | Withdrawal Volume/Dose | Total Doses | Best Use Case |
|—|—|—|—|—|—|
| 5mg vial | 1mL | 5mg/mL | 0.25mg | 50μL | 20 | Short pilot studies, dose-response testing |
| 10mg vial | 2mL | 5mg/mL | 0.5mg | 100μL | 20 | Standard 4-week research cycles |
| 15mg vial | 1.5mL | 10mg/mL | 0.3mg | 30μL | 50 | Extended protocols with daily administration |
| 20mg vial | 2mL | 10mg/mL | 0.5mg | 50μL | 40 | Multi-month studies requiring consistent dosing |
| 25mg vial | 2.5mL | 10mg/mL | 0.25mg | 25μL | 100 | Large-scale or long-duration research programs |

The 10mg vial reconstituted with 2mL bacteriostatic water represents the most common research format. It balances dose count (20 doses at 0.5mg each), measurement accuracy (100μL per dose), and refrigerated shelf life (28 days post-reconstitution). Larger vials (20mg, 25mg) provide economy of scale for extended studies but require completion within the 28-day bacteriostatic water stability window—unused peptide after that point risks microbial contamination even under refrigeration.

What If: MK-677 Dosing Scenarios

What If I Accidentally Reconstitute with Too Much Water?

Add the target volume of bacteriostatic water to the vial—if you overshoot by 0.5mL, you've diluted the solution beyond your intended concentration. The peptide content hasn't changed—only the concentration per mL. Recalculate your withdrawal volume using the new concentration. A 10mg vial intended for 2mL reconstitution (5mg/mL) accidentally diluted with 3mL now contains 3.33mg/mL. A 0.5mg target dose now requires 150μL instead of 100μL. Total dose count remains 20—you're just withdrawing more liquid per administration. The primary risk is exceeding syringe capacity for your target dose if dilution is severe.

What If My Vial Contains Visible Particles After Reconstitution?

Lyophilised peptides should dissolve completely into clear solution within 60 seconds of gentle swirling. Visible particles, cloudiness, or precipitate indicate either incomplete dissolution, contamination, or protein aggregation. Do not inject particulate solutions—aggregated peptides lose biological activity and increase injection site irritation risk. Gently swirl (never shake) the vial for another 30–60 seconds. If particles persist, the vial may have been exposed to temperature extremes during shipping or storage, denaturing the protein structure. Discard and replace. Real Peptides ships with cold packs and insulated packaging to prevent temperature excursions—but carrier delays can compromise stability.

What If I Need Doses Smaller Than My Syringe Can Measure?

Insulin syringes measure reliably down to 1μL (0.001mL) increments, but practical accuracy degrades below 10μL due to dead space in the needle hub and surface tension effects. If your target dose requires withdrawals below 10μL—common with highly concentrated solutions—increase reconstitution volume to raise per-dose withdrawal into the 25–50μL range. A 10mg vial reconstituted with 4mL water instead of 2mL creates 2.5mg/mL concentration. A 0.25mg dose now requires 100μL instead of 50μL—easier to measure accurately without changing total dose count. Alternatively, switch to a precision pipette for sub-10μL measurements if your protocol justifies the equipment investment.

The Unflinching Truth About MK-677 Vial Dosing

Here's the blunt answer: most researchers waste 10–20% of every vial because they don't account for dead volume. The solution remaining in the vial neck, adhering to interior glass surfaces, and trapped in the needle hub after each withdrawal adds up. A 2mL reconstituted vial theoretically contains 2000μL total—but you'll only extract 1800–1850μL in practice before the remaining liquid becomes inaccessible to the syringe needle. That 'lost' 150–200μL represents 7.5–10% of your total peptide content if you reconstituted at 5mg/mL—equivalent to 1.5–2 full doses.

The solution is straightforward: slightly overfill during reconstitution to compensate for dead volume. Instead of adding exactly 2mL bacteriostatic water, add 2.2mL. Your working concentration is now 4.54mg/mL instead of 5mg/mL—close enough that withdrawal volumes require minimal adjustment (110μL per 0.5mg dose instead of 100μL), but the extra 200μL accounts for the volume you'll lose to dead space. This costs nothing in solvent and recovers 1–2 doses per vial that would otherwise be wasted. Apply this across a 6-month protocol using 12 vials and you've recovered 12–24 doses—the equivalent of an entire extra vial.

The second truth: concentration stability degrades faster than most researchers assume. Bacteriostatic water extends usability to 28 days under ideal refrigeration (2–8°C), but that's a maximum ceiling—not a guarantee. Every temperature excursion above 8°C during storage accelerates peptide degradation. If your refrigerator door is opened 15 times daily (common in shared lab settings), internal temperature can spike to 10–12°C for 2–3 minutes per opening. Over 28 days, cumulative degradation reduces potency by 5–15% even when the solution appears clear and unchanged. Use reconstituted peptides within 21 days when possible—the final week carries measurable potency loss that dose calculations don't account for.

Peptide concentration isn't the only variable that affects how many doses vial MK-677 provides. Storage discipline, syringe technique, and realistic accounting for dead volume matter just as much as the math. The labs that stretch every vial to its theoretical maximum are the ones that integrate these details into standard operating procedure—not just the reconstitution formula.

Understanding how peptide content, reconstitution volume, and target dose interact determines whether you're running precise research protocols or guessing your way through dose administration. The vial label tells you total peptide mass—everything else is a function of how you prepare and handle the solution. Choose reconstitution volumes that place your withdrawals in the 25–200μL range for measurement accuracy. Factor HPLC-verified purity into dose count calculations. Account for 10% dead volume loss. Store reconstituted peptides at 2–8°C and use within 21 days for maximum potency retention. These aren't optional refinements—they're the baseline for reproducible results across multi-week research cycles.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

1. Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
2. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
3. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
4. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
5. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
6. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
7. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001